Sean Sullivan
Seminars
• How to design a scalable, modular manufacturing model to enable Phase II/III execution without overcommitting pre-commercial – including lessons from scaledown modeling to simulate future bottlenecks
• Strategic considerations in platform selection and core workflow standardization to support repeatability, reduce cost, and accelerate late-stage development
• Lessons from early investments in future-proofing critical processes – minimizing tech transfer complexity and enabling global trial expansion and real-world access
• How to leverage self-amplifying RNA (saRNA) to increase antigen expression and prolong immune stimulation – and why this matters for robust T cell priming in cancer vaccines
• Comparative insights on saRNA vs. conventional mRNA for driving cellular immune responses, and where each platform may hold distinct clinical advantages
• Considerations for integrating saRNA into individualized vaccine workflows, including formulation, dosing strategy, and patient variability
